Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepavax-Gene TF vs Engerix B in Neonates
NCT01349283Phase 3Completed
- Sponsor
- Crucell
- Start
- May 2011
- Primary completion
- Nov 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hepatitis b vaccine (recombinant) in hepatitis B (HBV) (6 arms), sponsored by Crucell. Primary endpoints: Seroconversion rate for subjects in Stratum 2 at Month 7 and Positivity for HBsAg for subjects in Stratum 1 at Month 12. Started May 2011; status: completed.
02
Drugs
hepatitis b vaccine (recombinant)
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01349283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349283.